Related Experiment Videos
[Cardiac indications for oral anticoagulation]
1Herz-Kreislauf-Zentrum, Kardiologie, Universitätsspital, Departement Innere Medizin, Zürich. marco.roffi@usz.ch
Praxis
|October 22, 2004
Summary
Long-term oral anticoagulation requires balancing benefits against bleeding risks. New anticoagulants may offer fixed-dose, monitoring-free alternatives to warfarin for preventing thromboembolic events.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Research
Context:
- Oral anticoagulation is crucial for managing thromboembolic events.
- Warfarin has been the long-standing standard treatment.
- Emerging oral anticoagulants show promise for improved patient management.
Purpose:
- To review the benefits and risks of long-term oral anticoagulation.
- To discuss current indications and controversial uses of anticoagulation.
- To highlight advancements in anticoagulant therapies.
Summary:
- Balancing the reduction of thromboembolic events against bleeding risks is essential for individual patients on long-term oral anticoagulation.
- Established indications include chronic atrial fibrillation, prosthetic heart valves, and left ventricular thrombus.
- The efficacy of anticoagulation in stable sinus rhythm with impaired left ventricular function and secondary coronary artery disease prevention remains debated.
- Novel oral thrombin inhibitors like ximelagatran demonstrate promising results.
- Future anticoagulants may offer fixed-dose administration without the need for monitoring, potentially replacing warfarin.
- Clinical trials are evaluating double antiplatelet therapy (aspirin and clopidogrel) for secondary prevention in atrial fibrillation.
Impact:
- Informs clinical decision-making regarding oral anticoagulation therapy.
- Highlights the potential shift towards more convenient and effective anticoagulant treatments.
- Guides future research in anticoagulant and antiplatelet therapies for cardiovascular disease.